Moreover, the suppression of CD86, an antigen presentation marker linked to T-cell priming and chronic inflammation, suggests that EVOOPE+ may dampen the interface between innate and adaptive immunity, a relevant target in atherosclerosis and metabolic syndrome [23]. The gene discussed is CD86; the disease is metabolic syndrome.